Teva Pharmaceutical Industries Limited

Dov Diller

Ben-Zion Dolitzky

Judith Aronhime

Barnaba Krochmal

Shlomit Wizel

Igor Lifshitz

Boaz Gome

Ben Zion Dolitzky

Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI.

Polymorphic Form XVI of fexofenadine hydrochloride

This invention encompasses methods of synthesizing olanzapine without solvents or by using low boiling organic solvents.

Methods of synthesizing olanzapine

The invention is directed to a series of novel crystalline olanzapine forms, in particular hydrated and solvated crystalline forms of olanzapine, methods of use in pharmaceutical compositions, and method of treating psychiatric disorders using the crystalline forms. One series of the crystalline forms are hydrates, i.e. water containing crystals, wherein water may be present in a ratio of about 2:1.5 to a ratio of about 1:3 olanzapine:water, while another includes solvates such as an isobutanol solvate. The olanzapine crystalline forms include Forms H, G, Y, X, K, S, Q, Z, and J.

Crystal forms, methods for their preparation and method for preparation of olanzapine

The present invention is directed to the novel forms of risperidone, designated Form A, Form B and Form E. Methods for their preparation are also disclosed. The present invention also relates to processes for making risperidone. Pharmaceutical compositions containing the new forms of risperidone and methods of using them are also disclosed.

Preparation of risperidone

Provided is a novel synthesis of quetiapine employing phase transfer catalyst.

Growing community of inventors

Jerusalem, Israel

Dov Diller